In Turkey, pharmaceutical products for human use cannot be
marketed unless they are authorized by the Ministry of Health
(“MoH”). In order to grant
pharmaceutical license andh marketing authorization, MoH requires
pharmaceutical companies to submit the results of their
pharmaceuticals' safety and efficacy tests, along with other
documents regarding the product.
In effect, pharmaceutical companies must invent and develop a
pharmaceutical product through intensive and time-consuming
research and development activities, then provide the results of
the toxicological and pharmacological tests and clinical trials to
MoH in order to commercially exploit their product. This is a long
and costly process for introducing new or more effective treatments
for patients.